CC BY-NC-ND 4.0 · Laryngorhinootologie 2022; 101(S 02): S243-S244
DOI: 10.1055/s-0042-1747005
Poster
Rhinology: Nasal cavity / Paranasal sinuses

Effect of Bevacizumab on endothelial cell proliferation and VEGF expression in patients with hereditary hemorrhagic telangiectasia (HHT) – an in vitro study

Haneen Sadick
1   Universitätsklinik für HNO-Heilkunde, Kopf- und Halschirurgie, Medizinische Fakultät Mannheim der Universität Heidelberg Mannheim
,
Elena Schäfer
1   Universitätsklinik für HNO-Heilkunde, Kopf- und Halschirurgie, Medizinische Fakultät Mannheim der Universität Heidelberg Mannheim
,
Christel Weiss
2   Medizinische Fakultät Mannheim der Universität Heidelberg, Medizinische Statistik und Biomathematik Mannheim
,
Nicole Rotter
1   Universitätsklinik für HNO-Heilkunde, Kopf- und Halschirurgie, Medizinische Fakultät Mannheim der Universität Heidelberg Mannheim
,
Richard Birk
3   Universitätsklinik für HNO-Heilkunde, Kopf- und Halschirurgie Marburg
,
CorneliaEmika Birk
3   Universitätsklinik für HNO-Heilkunde, Kopf- und Halschirurgie Marburg
,
Daniel Häussler
1   Universitätsklinik für HNO-Heilkunde, Kopf- und Halschirurgie, Medizinische Fakultät Mannheim der Universität Heidelberg Mannheim
› Author Affiliations
› Further Information
Also available at
 
 

    Previous studies have shown that the vascular endothelial growth factor VEGF plays a major role in angiogenesis and is upregulated in patients with hereditary hemorrhagic telangiectasia (HHT). The use of Bevacizumab as an anti-angiogenic treatment agent seems promising. The purpose of this in vitro study was to determine the efficacy and potential toxicity of Bevacizumab on cell proliferation and VEGF expression in endothelial cells of HHT patients.

    Endothelial cells cultures of three HHT patients and a HUVEC cell line as a control were incubated with different concentration levels (2, 4, 6, 8, 10 mg/ml) of Bevacizumab. After 24, 48 and 72 hours, the cell proliferation and the VEGF expression in the supernatant of all cell culture probes were measured.

    All endothelial cells incubated with Bevacizumab showed initially a decrease in cell proliferation. The cell proliferation recovered within 72 hours in cell cultures incubated with concentration levels of up to 4 mg/ml whereas those incubated with higher concentration levels showed a continuous decline in their cell proliferation with signs of cell apoptosis. The VEGF expression decreased after 24 hours in cell cultures incubated with Bevacizumab concentration levels of 2 and 4 mg/ml, but increased again after 48 hours. Bevacizumab concentration levels of 10 mg/ml showed a continuous decline of VEGF expression without any tendency of recovery.

    Translating these results into daily clinical practice, this in vitro study suggests that intranasal submucosal applications of Bevacizumab in HHT patients should not exceed the concentration level of 4 mg/ml. Higher Bevacizumab concentration levels are at a higher risk of a toxic effect on endothelial cells as they jeopardize their cell proliferation.


    #

    Conflict of Interest

    The author declares that there is no conflict of interest.

    Publication History

    Article published online:
    24 May 2022

    © 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

    Georg Thieme Verlag
    Rüdigerstraße 14, 70469 Stuttgart,Germany